RxDoctor Payments Data

Vikas Varma, MD

Neurology · Fresh Meadows, NYNPI 1306870720

Payments from drug & device makers

$11,309in general payments, 2019–2025

Across 353 payments — averaging $32.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$3K
  • AbbVie$2K
  • Stryker$1K
  • Pfizer$816
  • Valinor Pharma, LLC$554
  • Alphatec Spine, Inc$505
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$8007%
  • Travel & lodging$1,12910%
  • Food & beverage$7,76269%
  • Education$1,61714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,309 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$224,177
Medicare patients
228
Services billed
2,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate76$119,315
MovantikNaloxegol Oxalate250$100,650
UbrelvyUbrogepant26$46,534
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,599$35,714
Diclofenac Sodium282$26,236
Oxycodone Hcl1,209$22,361
Lidocaine202$18,338
Aimovig AutoinjectorErenumab-Aooe25$17,854
ZavzpretZavegepant Hcl16$16,471
Gabapentin1,673$16,013
Tizanidine Hcl737$15,276
QuliptaAtogepant12$12,147
LyricaPregabalin11$10,033
Scopolamine109$8,103
Entacapone112$7,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret, Lyrica$816$145,820103 claims
AbbVieUbrelvy, Qulipta$1,628$58,68138 claims
Scilex Pharmaceuticals Inc.Ztlido$179$6,06015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →